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Misfolding and aggregation of amyloid β (Aβ) are key features of Alzheimer's disease (AD) pathogenesis,
but the molecular events controlling this process are not known in detail. In vivo, Aβ aggregation and
plaque formation occur in the interstitial ﬂuid of the brain extracellular matrix. This ﬂuid communicates
freely with cerebrospinal ﬂuid (CSF). Here, we examined the effect of human CSF on Aβ aggregation
kinetics in relation to AD diagnosis and carrier status of the apolipoprotein E (APOE) ε4 allele, the main
genetic risk factor for sporadic AD. The aggregation of Aβ was inhibited in the presence of CSF and,
surprisingly, the effect was more pronounced in APOE ε4 carriers. However, by fractionation of CSF using
size exclusion chromatography, it became evident that it was not the ApoE protein itself that conveyed
the inhibition, since the retarding species eluted at lower volume, corresponding to a much higher
molecular weight, than ApoE monomers. Cholesterol quantiﬁcation and immunoblotting identiﬁed high-
density lipoprotein particles in the retarding fractions, indicating that such particles may be responsible
for the inhibition. These results add information to the yet unresolved puzzle on how the risk factor of
APOE ε4 functions in AD pathogenesis.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's disease (AD) is a devastating neurodegenerative
disorder that increases with age. Given the suffering for the pa-
tients and relatives, costs for society are enormous. The neuro-
pathological hallmarks of AD are amyloid β (Aβ) aggregates called
amyloid plaques and neuroﬁbrillary tangles consisting of hyper-
phosphorylated tau protein (Blennow et al., 2006). Cerebral β-
amyloidosis in AD, along with ﬁndings of several causative mu-
tations affecting Aβ production and/or aggregation in familial
forms of AD, point to the signiﬁcant role Aβ plays in the etiology of
the disease (Glenner et al., 1984; Masters et al., 1985; Bertram and
Tanzi, 2012). Aβ is produced from the amyloid precursor protein
(APP; a type I transmembrane protein highly but not exclusively
expressed in neurons) by sequential cleavages by β- and γ-B.V. This is an open access article u
atory, Sahlgrenska University
. Padayachee).secretase (Andreasson et al., 2012). This processing of APP releases
several Aβ peptides of different lengths. Aβ1-40 is the most
abundant Aβ form, whereas a 42 amino acid long, less abundant
form (Aβ1-42) is the most aggregation-prone and builds up the
cores of the Aβ plaques seen in AD brains (Portelius et al., 2010).
The human APOE gene encodes the ApoE protein which is a 299
residue apolipoprotein abundant in biological ﬂuids and involved
in the transport of lipids (Verghese et al., 2013). The gene has three
alleles: APOE ε2, ε3 and ε4, and the translated ApoE proteins differ
in sequence, structure and afﬁnity for Aβ (Frieden and Garai, 2012;
Mahley and Rall, 2000), thereby inﬂuencing the aggregation of Aβ
(Strittmatter et al., 1993). The APOE ε4 allele is strongly associated
with the sporadic late-onset AD (Corder et al., 1993; Liu et al.,
2013; Poirier et al., 1993). The mechanism of this association re-
mains unknown but seems to be intimately linked to increased
risk of brain Aβ aggregation in ε4 carriers (Poirier et al., 1993).
The strong genetic link between the APOE ε4 allele and cerebral
β-amyloidosis suggests that cholesterol may play a direct role in
the pathogenesis of AD (Puglielli et al., 2003; Liu et al., 2013). Li-
poprotein particles are cholesterol-rich particles produced in thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(CSF) (Ladu et al.., 1998). Lipoprotein particles are relatively high
afﬁnity Aβ binding proteins with a Kd in the nanomolar range,
capable of regulating Aβ aggregation (Cole and Ard, 2000). Plasma
contains three classes of lipoproteins in order of increasing size:
very low density lipoproteins (VLDL), low density lipoproteins
(LDL) and high density lipoproteins (HDL) (LaDu et al.., 1998). In
plasma, APOE ε4 tends to associate with VLDL particles, and APOE
ε3 prefers to associate with high density HDL particles (Puglielli
et al., 2003). In contrast to plasma, most CSF lipoproteins are HDL-
like in both density and size (Holtzman et al., 1999; Borghini et al.,
1995).
In vivo, Aβ aggregation and plaque formation occur in the in-
terstitial ﬂuid of the brain extracellular matrix. This ﬂuid com-
municates freely with CSF. Here, we examined Aβ aggregation
kinetics in the presence of human CSF to test if CSF from AD pa-
tients was different from CSF from cognitively normal individuals
in this regard and whether any AD-associated differences in Aβ
aggregation kinetics were related to APOE genotype. Results from
biochemical analysis of CSF fractions indicate that the factor re-
sponsible for the APOE genotype-associated effect on the ag-
gregation kinetics of Aβ1-42 is not the ApoE protein itself but
rather the HDL particles of which ApoE is a constituent.Fig. 1. Scatter plots of half time for ﬁbril formation, t½ (mean of three replicates)
for the three groups in cohort 1 (A); scatter plots of half time for ﬁbril formation, t½
(mean of three replicates) for the four groups in cohort 2 (B).2. Results
The formation of Aβ42 ﬁbrils was monitored as a function of
time using a highly reproducible thioﬂavin T ﬂuorescence assay
(Hellstrand et al., 2010; Cohen et al., 2013). The aggregation of
recombinant Aβ (the full 42 amino acid sequence with an extra
N-terminal methionine, which does not inﬂuence aggregation ki-
netics M1-42) (Walsh et al., 2009), here called Aβ42, was mon-
itored in 20 mM Hepes/NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0 at
37 °C under quiescent condition in the presence of 10% CSF from
two different cohorts (Table 1).
There was a clear retardation of Aβ42 aggregation in the pre-
sence of CSF, mainly seen as a prolonged lag phase, observed from
both cohorts. Scatter plots of the resulting t½ values for samples
from cohorts A and B are shown in Fig. 1. While the difference
between healthy controls and AD lacking an APOE ε4 allele was not
statistically signiﬁcant, the more profound retardation observed
for AD patients carrying at least one APOE ε4 allele was statistically
signiﬁcant (pr0.02)..
To explore the molecular determinants behind the observed
retardation, CSF was fractionated on a superose 6 size exclusion
chromatography, and the aggregation kinetics was measured for
Aβ42 solutions supplemented with samples from the resulting
fractions. The observed aggregation curves were sigmoidal in ap-
pearance with a lag phase, a growth phase and a ﬁnal plateau
(Fig. 2). The half time (t½) of aggregation was extracted from each
curve as the point in time where the ThT ﬂuorescence is half-way
in between the initial base line value (lag) and the ﬁnal plateauTable 1
Demographic data of two independent case-control cohorts of CSF samples obtained from
Spain, and the second cohort from subjects in the Piteå Dementia Project.
Cohort 1
Controls AD
ApoE4 () ApoE4 (þ)
Number of subjects 25 10 15
Age/years mean(SD) 64.4(8.8) 68.4(7.9) 59.9(7.3)
Gender (# females) 16 8 8value. Fractions 14–18, speciﬁcally fraction 15 was found to retard
Aβ42 ﬁbril formation compared to buffer, primarily observed as an
extension of the lag phase (Fig. 2). Fractions 14–18 retarded Aβ42
aggregation signiﬁcantly, and fraction 15 produced the longest
extension of the lag phase (t½¼16970.1 min) compared to the
other fractions. The cholesterol concentration was high in fractions
14–17, and the highest value (0.1770.002 mg/ml) was observed
for fraction 15 (Fig. 3). Immunoblot analysis (Fig. 4) identiﬁed
bands for ApoE (36 kDa) in fractions 8–17, ApoA-I (29 kDa) in
fractions 10–18, and ApoJ (39.8 kDa) in fractions 13–15, in-
dicating that these fractions were rich in apolipoproteins. The
bands were most intense for fraction 14–15 (ApoE), 15 (ApoA-I)
and 14 (ApoJ). This ﬁnding was signiﬁcant as it coincides closelyAlzheimer's disease and Other Cognitive Disorders Unit, Hospital Clinic, Barcelona,
Cohort 2
Controls AD
ApoE4 (/) ApoE4 (þ/) ApoE4 (þ/þ)
20 21 20 14
69.8(4.4) 80.2(5.5) 76.6(7.7) 74.5(6.9)
10 12 11 9
Fig. 2. Examples of sigmoidal aggregation curves monitored by Thioﬂavin-T
ﬂuorescence, depicting non-fractionated CSF (solid lines), a fraction after gel ﬁl-
tration showing the most pronounced inhibition of the kinetics (fraction 15, dashed
lines). The kinetics in the absence of rate-affecting substances is within error the
same as for fraction 8 (dotted lines).
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Fig. 3. A bar graph expressing t½ per a CSF fraction. Blue bars represent t½ values
and white bars represent cholesterol concentration (mean of two replicates).
Fraction 15 displayed the greatest t½ values of 169 min70.1 min. Fraction 15 also
contained the highest cholesterol concentration of 0.17 mg/ml70.002 mg/ml,
compared to the other fractions.
Fig. 4. Immunoblots depicting bands for ApoE (36 kDa) (A); ApoA-I (28 kDa)
(B); ApoJ (39.8 kDa) (C); control membrane, incubated with only with secondary
antibody (D). Lane number corresponds to fraction number. The ﬁrst lane marked
MW is the molecular weight marker and the second lane marked CSF was the
control used.
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Fractions containing lower molecular weight substances, com-
pared to HDL complexes, were all found to have no effect on the
aggregation kinetics (data not shown)....3. Discussion
CSF was used as a surrogate matrix for brain extracellular ﬂuid
and it was found that CSF retarded Aβ aggregation in an APOE ε4-
dependent manner. After chromatographic separation, fraction 15
inﬂuenced aggregation kinetics the most and was found to contain
HDL based on cholesterol and immunoblot analyses. Our data
suggest that APOE ε4 affects the structure of HDL or the interaction
of HDL with Aβ42 to further inhibit Aβ aggregation.
Previous papers have shown that Aβ aggregation is inhibited by
CSF and that the extent of inhibition is dependent on the type of
APOE allele present (Chauhan et al., 1996; Wisniewski et al., 1993).
Chauhan et al. revealed that CSF from control groups with an APOE
ε3/3 genotype, resulted in faster Aβ aggregation than those with
APOE ε4/4 or APOE ε3/2 genotype. Conversely, the APOE ε4/4
genotype was associated with a slower Aβ aggregation effect. Our
current study has supported Chauhan et al., as it was observed that
CSF inhibits Aβ aggregation with CSF from APOE ε4 carriers.
Wisniewski et al.., used synthetic Aβ1-40 to examine the in-
hibitory effect of CSF. In the current study, we used recombinant
Aβ (M1-42) to ensure that the Aβ42 preparations were not con-
taminated by C-terminally truncated species that are common in
synthetic Aβ1-42 preparations, due to suboptimal coupling efﬁ-
ciency in chemical peptide synthesis and known to inﬂuence Aβ1-
42 ﬁbrillization kinetics (Finder et al., 2010).
We fractionated CSF to isolate the retarding factor and the co-
incidence of strongest retarding effect and elution of HDL-like
particles suggest that such particles may be the component in CSF
which is responsible for the Aβ inhibition effect. These particles
contained apolipoproteins ApoA-I, ApoE and ApoJ that have been
previously shown to bind to soluble Aβ (LaDu et al.., 1995, Kou-
dinov et al., 1994). A similar experiment was performed by LaDu
et al., using FPLC in tandem with Superose 6 columns. Western
blot analysis of SDS-PAGE of selected FLPC fractions conﬁrmed the
co-localization of ApoE and Aβ to the same fractions (Ladu et al..,
2012). Normally, lipoprotein particles are separated by ultra-
centrifugation in potassium bromide gradients due to the density
at which they ﬂoat. However the high salt gradients and shear
force may disturb the lipoprotein complex (Ladu et al.., 1998).
Hence size exclusion chromatography was performed to preserve
the native particle composition. We note however, that the re-
tarding effect was retained also after ammonium sulfate fractio-
nation (data not shown).
Cholesterol quantiﬁcation is a commonly used method to
conﬁrm the presence of HDL particles in plasma fractions (Gus-
tafsson et al., 2007). In our experiments, cholesterol was quanti-
ﬁed in fractions after gel ﬁltration and high concentrations cor-
related with the retardation effect. This ﬁnding, along with the
immunochemical detection of several HDL-associated proteins
(ApoE, ApoA and ApoJ), led us to conclude that HDL-like particles
were present in these fractions and that they were responsible for
retarding Aβ aggregation. It has further been shown that the
ApoE- and ApoJ-containing lipoproteins are similar in size and
density to plasma HDL and that ApoA-I make up 70% of the HDL
particle (Fagan et al., 1999; Koudinov et al., 1996; Rached et al.,
2015). Further, CSF does not contain other lipoprotein particles,
such as VLDL or LDL (Otvos, 1999), which makes the association of
the retarding effect of CSF on Aβ42 aggregation with HDL-like
particles even stronger.
ApoE was detected in several non-retarding CSF fractions. Thus,
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with an APOE ε4-associated alteration in HDL composition and/or
structure. The delay in Aβ42 aggregation, with the most pro-
nounced effect being an extension of the lag phase, has the same
signature as recently observed for the chaperone DNAJ B6, which
was inferred to mainly inhibit primary nucleation through inter-
action with nuclei or small aggregates (Mansson et al., 2014) to
prevent their further growth into ﬁbrils. While inhibition of sec-
ondary nucleation or elongation produces distinctly different ef-
fects of aggregation curves (Arosio et al., 2014; Cohen et al., 2015),
the HDL-like particles seem to primarily inhibit primary nuclea-
tion. Such an effect could arise from binding of monomer, leading
to lower effective concentration, or binding of nuclei or small ag-
gregates to inhibit their further growth (Arosio et al., 2014).
The enhanced retardation observed here for APOE ε4 carriers
may reﬂect their triggering of a defense mechanism to produce
higher levels of HDL-like particles or more effective HDL-like
particles to limit Aβ42 aggregation. Reports have also shown that
APOE ε4 is associated with increased Aβ oligomer formation (Ha-
shimoto et al., 2012; Garai et al., 2014). Inhibition of Aβ aggrega-
tion might result in and be consistent with increased amounts of
soluble Aβ oligomers as shown in the above reports. This argu-
ment is well supported by two papers from our group, where it
was stated that the toxic oligomeric species are predominantly
formed from monomeric peptide molecules through a ﬁbril-cata-
lyzed secondary nucleation reaction (Cohen et al., 2013, 2015).
One limitation of the present study is that it was not possible to
compare the effect on Aβ aggregation with respect to APOE ε4
status between controls and AD cases. However, this does not af-
fect the interpretability of the major ﬁndings in the study.4. Conclusion
CSF retards Aβ42 aggregation in an APOE ε4-dependent man-
ner with the strongest effect observed for APOE ε4 carriers. The
effect correlates with the concentration of HDL-like particles in
size exclusion fractions of CSF, strongly suggesting HDL-like par-
ticles as the retarding factor in CSF. The kinetic signature with an
extended lag phase as the most pronounced effect implies inter-
ference with primary nucleation.5. Materials and methods
5.1. Patients
Two independent case-control cohorts of CSF samples were
used in this study. Cohort 1 was prospectively recruited from the
Alzheimer's disease and Other Cognitive Disorders Unit, Hospital
Clinic, Barcelona, Spain, and consisted of 25 controls and 25 CE
patients. Ten of the AD patients had no APOE ε4 allele, while 15
had at least one ε4 allele. All of the controls were APOE ε4 nega-
tive. The second cohort consisted of 20 healthy controls and 59
selected, based on the number of APOE alleles, AD cases from
subjects in the Piteå Dementia Project (Andreasen et al., 1999). The
AD cases comprised of 20 patients with no APOE ε4 allele, 20 with
one APOE ε4 allele, and 19 with two APOE ε4 alleles. For the
controls no APOE status was available. The demographics of the
cohorts are shown in Table 1. All AD patients fulﬁlled the NINCDS-
ADRDA criteria for “probable” AD according to the old criteria
(Mckhann et al., 1984) for cohort 1 and the revised criteria
(Mckhann et al., 2011) for cohort 2. The study was carried out in
accordance with the Declaration of Helsinki.5.2. Isolation of Aβ42 monomer and aggregation assay
Aβ (M1-42), here called Aβ42, was expressed in E. coli from a
synthetic gene (Walsh et al., 2009). Recombinant Aβ42 was pur-
iﬁed using ion exchange and gel ﬁltration chromatography to
generate Aβ42 monomers, which were then lyophilized and stored
as dried powder at 20°C. Each day, one lyophilized Aβ42 aliquot
was dissolved in 1 ml 6 M GuHCl and the monomer was isolated
by gel ﬁltration on a 130 cm Superdex 75 column in 20 mM
Hepes/NaOH, 1 mM CaCl2, pH 8.0. The center of monomer peak
was collected in low-binding Eppendorf tube (Genuine Axygen
Quality, Microtubes, MCT-200-L-C) on ice and the concentration
determined from the integrated absorbance of the collected frac-
tion of the chromatogram using ε280¼1400 L mol1 cm1. For all
CSF fractions, the Aβ42 monomer, was diluted with Hepes buffer
(20 mM) containing NaCl (0.14 M) and ThT was added from a
concentrated stock to obtain the ﬁnal concentrations of 4 mM Aβ42
monomer and 10 mM ThT in 20 mM Hepes/NaOH, 0.14 M NaCl,
1 mM CaCl2, pH 8.0. Each CSF fraction was supplemented with
buffer from a concentrated stock, pH adjusted, and diluted to ob-
tain 20% CSF in 20 mM Hepes/NaOH, 0.14 M NaCl, 1 mM CaCl2, pH
8.0, and mixed 1:1 with the Aβ42 solution, so that the ﬁnal sam-
ples contained 2 mM Aβ42, 6 mM ThT and 10% CSF. The ﬁnal con-
centration of exogenous Aβ42 (2 μM¼9 μg/ml) is four orders of
magnitude higher than what is found in CSF (1 ng/ml), of which
10% (v/v) is present in the reaction mixture. Therefore any con-
tribution of endogenous Aβ42 from the CSF can be neglected. The
samples were mixed in low-binding tubes on ice and loaded into a
black 96-well plate with clear bottom, half-area and non-binding
surface (Corning 3881, Sigma Aldrich). The kinetic experiment was
started by placing the plate at 37 °C in a plate reader (BMG
Fluostar Omega, Optima or Galaxy). The ﬂuorescence was read
though the bottom of the plate using a 340 nm excitation ﬁlter and
a 380 nm emission ﬁlter every minute for up to 350 min. The half
time of aggregation (t½) was deﬁned as the point where the
ﬂuorescence minus initial baseline reached half the value of the
equilibrium plateau and was extracted from all curves by ﬁtting a
sigmoidal function to the ﬂuorescence intensity, y, as a function of
time, t:
( )( )= + ( + − −y a b/ 1 exp t t k1/2
and plotted relative to CSF fraction number.
5.3. Fractionation of CSF by gel size exclusion chromatography
A pool of leftover, non-traceable CSF samples (40 ml) from
clinical routine analysis of normal (i.e. non-AD) patients was
centrifuged at 2250 g for 10 min at room temperature (25 °C).
The supernatant was transferred by pipetting. After continuous
mixing, 1 ml was aliquoted and frozen at 20 °C. Centrifuged CSF
(4 ml) was concentrated using an amicon ﬁlter (10 kDa MWCO)
and 0.2 ml of the concentrate was applied independently to Su-
perose 6 10/300 GL column. All protein fractions were eluted with
isocratic PBS buffer (0.14 M NaCl, 0.0027 M KCl and 0.010 M
phosphate, pH 7.4); ﬂow rate 0.5 ml/min, 1 ml fractions). All frac-
tions from CSF were stored at 20 °C and tested against the ThT
kinetic assay.
5.4. Cholesterol analysis
Cholesterol was quantiﬁed in all fractions from gel exclusion
chromatography, using commercially available kits (Cholesterol
Inﬁnity Kit, Thermoﬁsher). The cholesterol standard was MCC Cal
2 (Abbott Laboratories, USA), which contained 10.05 mM choles-
terol. Each fraction, standard and blank (PBS), respectively, was
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Liquid Stable reagent (100 ml) was added to the wells and mixed
well (15x) on the ELISA plate reader at 37 °C for 15 min. Absor-
bance was recorded at 500 nm and 660 nm in the ELISA plate
reader. Readings at 660 nm were subtracted from readings at
500 nm to correct for optical imperfections in the plate.
5.5. Immunoblotting
Biotinylated molecular weight marker (Sigma Aldrich, Cat No.
B2787) was diluted 1:20 in 1 Nu-PAGE LDS sample buffer
(without DTT). CSF not subjected to size exclusion chromato-
graphy was used as positive control and incubation of membrane
with no primary antibody was used as negative control. Fractions
8–20 from size exclusion chromatography were diluted 2 with
Nu-PAGE LDS sample buffer containing 0.5 M DTT. Undiluted CSF
fractions were tested against the ApoJ antibody. The molecular
weight marker, along with all fractions, including CSF, were se-
parated by electrophoresis in NU-PAGE 10% Bis-Tris gels (Invitro-
gen Corporation) using the Nu-PAGE mini-gel system (Xcell II
Mini-Cell [Novex, San Diego, CA, USA]). The proteins were trans-
ferred (0.7 mA/cm2) to Immobilon PVDF membranes (Millipore
Corporation, Billerica, MA, USA) using the semi-dry blotting
technique (Trans-Blot semi-dry Transfer cell). Blocking was per-
formed for 1 h at room temperature (RT) using 5% dry milk pow-
der in PBS-T (0.05% v/v Tween 20) (Blocking grade blocker, Non-
Fat dry milk, Bio-Rad Laboratories, USA). Incubations with the
primary antibodies (diluted 1:2000 in 5% dry milk) were per-
formed overnight at þ4 °C. The following primary antibodies were
used to monitor the presence of lipoproteins in CSF: monoclonal
mouse anti-human apolipoprotein E antibody; monoclonal mouse
anti-human apolipoprotein A1 antibody; monoclonal mouse anti-
human apolipoprotein J/Clusterin antibody (Novus Biologicals,
Europe). The membranes were washed for 6  10 min in PBS-T
(PBS with 0.05% v/v Tween 20) and then incubated for 1 h at room
temperature (RT) with biotinylated anti-mouse IgG antibody
(Vector Laboratories, Burlingame, CA, USA) (1 mg/ml), diluted
1:3000 in PBS-T. A second PBS-T wash was performed for
610 min after which the membranes were incubated for 1 h at
RT with streptavidin-biotinylated horseradish peroxidase complex
(GE Healthcare UK Limited, Buckinghamshire, UK) diluted 1:3000
in PBS-T. Following 6  10 min washes, the membranes were
developed for 2 min with Amersham ECL select Immunoblot de-
tection reagent (GE Healthcare) solution according to the manu-
facturer’s instructions. The emitted signal was detected by a Fuji-
ﬁlm LAS-3000 System (FUJIFILM Corporation).Acknowledgments
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